Deal protects world’s biggest selling drug from biosimilar erosion
AbbVie and Samsung Bioepis resolve patent litigation over arthritis drug Humira
AbbVie has settled a legal case with biosimilars company Samsung Bioepis over Imraldi, the South Korean company’s proposed version of AbbVie’s blockbuster TNF inhibitor Humira (adalimumab). Bioepis will receive a non-exclusive license allowing it to sell the biosimilar in the US from June 2023. In the EU, where the patent expires sooner, the licence period will begin this coming October.